FULC vs. NUVB, PRTA, CRON, GHRS, BCAX, VERV, MNMD, DNTH, AVXL, and OPT
Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Nuvation Bio (NUVB), Prothena (PRTA), Cronos Group (CRON), GH Research (GHRS), Bicara Therapeutics (BCAX), Verve Therapeutics (VERV), Mind Medicine (MindMed) (MNMD), Dianthus Therapeutics (DNTH), Anavex Life Sciences (AVXL), and Opthea (OPT). These companies are all part of the "pharmaceutical products" industry.
Fulcrum Therapeutics vs.
Nuvation Bio (NYSE:NUVB) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 5.1% of Nuvation Bio shares are held by company insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Fulcrum Therapeutics received 50 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 80.00% of users gave Nuvation Bio an outperform vote while only 61.25% of users gave Fulcrum Therapeutics an outperform vote.
Fulcrum Therapeutics' return on equity of -7.31% beat Nuvation Bio's return on equity.
Nuvation Bio has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.
In the previous week, Fulcrum Therapeutics had 1 more articles in the media than Nuvation Bio. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 2 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.97 beat Fulcrum Therapeutics' score of 0.44 indicating that Nuvation Bio is being referred to more favorably in the media.
Nuvation Bio presently has a consensus price target of $8.20, indicating a potential upside of 271.88%. Fulcrum Therapeutics has a consensus price target of $9.33, indicating a potential upside of 142.11%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nuvation Bio is more favorable than Fulcrum Therapeutics.
Nuvation Bio has higher earnings, but lower revenue than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Nuvation Bio and Fulcrum Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Fulcrum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulcrum Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FULC) was last updated on 2/21/2025 by MarketBeat.com Staff
Free FULC Stock Alerts